| Author | Grenfell, Rafaella Fortini Queiroz | |
| Author | Almeida, Nathalie Bonatti Franco | |
| Author | Filgueiras, Priscilla Soares | |
| Author | Corsini, Camila Amormino | |
| Author | Gomes, Sarah Vieira Contin | |
| Author | Miranda, Daniel Alvim Pena de | |
| Author | Lourenço, Adelina J. | |
| Author | Martins Filho, Olindo Assis | |
| Author | Oliveira, Jaquelline Germano de | |
| Author | Carvalho, Andrea Teixeira | |
| Author | Campos, Guilherme RF | |
| Author | Nogueira, Maurício Lacerda | |
| Author | Alves, Pedro Augusto | |
| Author | Fernandes, Gabriel da Rocha | |
| Author | Castilho, Leda dos Reis | |
| Author | Lima, Túlio Macedo | |
| Author | Abreu, Daniel Paiva Barros de | |
| Author | Alvim, Renata Guimaraes Ferreira | |
| Author | Silva, Thais Barbara de Souza | |
| Author | Jeremias, Wander de Jesus | |
| Author | Otta, Dayane Andriotti | |
| Author | Azevedo, Ana Caroline Campi | |
| Access date | 2023-08-31T12:11:05Z | |
| Available date | 2023-08-31T12:11:05Z | |
| Document date | 2022 | |
| Citation | GRENFELL, Rafaella Fortini Queiroz et al. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): a one year period follow up phase 4 study. Frontiers In Immunology, v. 13, p. 1-13, 2022.doi.org/10.2139/ssrn.4070408. | en_US |
| ISSN | 1664-3224 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/60275 | |
| Language | eng | en_US |
| Publisher | Frontiers | en_US |
| Rights | restricted access | en_US |
| Title | Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): a one year period follow up phase 4 study | en_US |
| Type | Article | en_US |
| Abstract | Background: Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.
Methods: We bring pioneering contributions on the maintenance of the immune response over a year on a real-life basis study in individuals who underwent vaccination with two doses of CoronaVac and BNT162b2 booster after 6-months of primary protocol.
Findings: Elevated levels of anti-spike IgG antibodies were detected after CoronaVac vaccination, which significantly decreased after 80 days and remained stable until the introduction of the booster dose. Heterologous booster restored antibody titers up to-1·7-fold, changing overall seropositivity to 96%. Titers of neutralising antibodies to the Omicron variant were lower in all timepoints than those against Delta variant. Individuals presenting neutralising antibodies against Omicron also presented the highest titers against Delta and anti-Spike IgG. Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. A stronger interaction between those mediators was noted over time. Prior exposure to the virus leaded to a more robust cellular immune response and a rise in antibody levels 60 days post CoronaVac than in individuals with no previous COVID-19. Both vaccines were safe and well tolerated among individuals.
Interpretation: Our data approach the effectiveness of CoronaVac association with BNT162b2 from the clinical and biological perspectives, aspects that have important implications for informing decisions about vaccine boosters. | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Infectious Diseases. College of Veterinary Medicine. University of Georgia. Athens, GA, United States | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Infectious Diseases. College of Veterinary Medicine. University of Georgia. Athens, GA, United States | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Hospital da Baleia. Benjamin Guimarães Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Laboratorio de Imunologia Celular e Molecular. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil | en_US |
| Affilliation | Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil/Hospital de Base. São José do Rio Preto, SP, Brazil/Department of Pathology, University of Texas Medical Branch. Galveston, TX, United States | en_US |
| Affilliation | Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Biosystems Informatics. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil | en_US |
| Affilliation | Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil | en_US |
| Affilliation | Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil | en_US |
| Affilliation | Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil | en_US |
| Affilliation | Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Laboratorio de farmacologia experimental. Faculdade de Farmácia. Universidade Federal de Ouro Preto. Ouro Preto, MG, Brazil | en_US |
| Affilliation | Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil | en_US |
| Subject | SARS-CoV-2 | en_US |
| Subject | COVID-19 | en_US |
| Subject | vaccine | en_US |
| Subject | immune response | en_US |
| Subject | coronavac | en_US |
| Subject | BNT162b2 | en_US |
| Subject | heterologous booster | en_US |
| Embargo date | 3100-12-31 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
